Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs
New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment
People with HIV and HCV co-infection who have fibrosis stages F2 and above should be prioritised for new anti-HCV therapies
Sofosbuvir plus daclatasvir for 12 weeks cures HCV for most people with HIV/HCV co-infection
Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis
Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration
Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C
